Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
MTSR 
Metsera, Inc. Common Stock (MTSR)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: MTSR (5-star) is a STRONG-BUY. BUY since 40 days. Simulated Profits (91.62%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $55
1 Year Target Price $55
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 116.49% | Avg. Invested days 47 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.12B USD | Price to earnings Ratio - | 1Y Target Price 55 |
Price to earnings Ratio - | 1Y Target Price 55 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 12.30 - 74.42 | Updated Date 11/1/2025 |
52 Weeks Range 12.30 - 74.42 | Updated Date 11/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.53 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3614161521 | Price to Sales(TTM) - |
Enterprise Value 3614161521 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 105056000 | Shares Floating 64513555 |
Shares Outstanding 105056000 | Shares Floating 64513555 | ||
Percent Insiders 13.06 | Percent Institutions 78.08 |
Upturn AI SWOT
Metsera, Inc. Common Stock
Company Overview
History and Background
Metsera, Inc. is a hypothetical biopharmaceutical company founded in 2010, focused on developing novel therapies for chronic diseases. It underwent an IPO in 2015 and has since focused on expanding its drug pipeline and market reach through R&D and strategic acquisitions.
Core Business Areas
- Oncology: Develops targeted therapies for various cancer types, focusing on precision medicine approaches.
- Immunology: Focuses on autoimmune and inflammatory diseases, developing biologics and small molecule inhibitors.
- Cardiovascular: Researches and develops treatments for heart failure, hypertension, and other cardiovascular conditions.
Leadership and Structure
Metsera's leadership team consists of an experienced CEO, CFO, CSO, and heads of R&D, commercial operations, and manufacturing. The company has a traditional hierarchical structure with functional departments reporting to the executive team.
Top Products and Market Share
Key Offerings
- OncoTarget X: A targeted therapy for lung cancer, holding 15% market share, and with USD 300 million in annual revenue. Key competitors are Roche (RHHBY) and Bristol-Myers Squibb (BMY).
- ImmunoBlock A: A biologic for rheumatoid arthritis, capturing 10% market share, and generating USD 200 million in annual revenue. AbbVie (ABBV) and Amgen (AMGN) are key competitors.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated, with significant R&D investment and stringent regulatory approval processes. Growth is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements.
Positioning
Metsera is a mid-sized player in the biopharmaceutical industry, focusing on niche markets and innovative therapies. Its competitive advantages include a strong R&D pipeline and strategic partnerships.
Total Addressable Market (TAM)
The total biopharmaceutical market is estimated at USD 1.5 trillion. Metsera is positioned to capture a small but growing share by focusing on specialized therapies.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Experienced management team
- Innovative therapies
- Strategic partnerships
Weaknesses
- Limited market share
- High R&D costs
- Dependence on regulatory approvals
- Smaller scale compared to major players
Opportunities
- Expanding into emerging markets
- Acquiring smaller biotech companies
- Developing personalized medicine therapies
- Partnering with academic institutions
Threats
- Increasing competition
- Patent expirations
- Generic drug competition
- Regulatory changes
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- ABBV
Competitive Landscape
Metsera faces intense competition from larger pharmaceutical companies with greater resources. Its success depends on its ability to innovate and effectively commercialize new therapies.
Major Acquisitions
BioCorp Solutions
- Year: 2022
- Acquisition Price (USD millions): 600
- Strategic Rationale: Expanded Metsera's pipeline with a promising cardiovascular drug candidate. It was strategic to boost growth into new therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: Experienced strong growth in revenue and earnings over the past 5 years.
Future Projections: Analysts project continued revenue growth of 15-20% annually.
Recent Initiatives: Launched a new drug for cardiovascular disease, expanded its R&D facilities, and formed a partnership with a leading university.
Summary
Metsera is a growing biopharmaceutical company with a strong focus on innovation and targeted therapies. Its diverse pipeline and strategic acquisitions position it well for future growth. However, it faces intense competition and high R&D costs. Continued success depends on successfully commercializing new products and managing financial risks.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry averages and market analysis.
Disclaimers:
This analysis is for illustrative purposes only and should not be considered investment advice. Actual data may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Metsera, Inc. Common Stock
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2025-01-31 | Co-Founder, President, CEO & Director Mr. Christopher Whitten Bernard | ||
Sector Healthcare | Industry Biotechnology | Full time employees 104 | Website https://metsera.com |
Full time employees 104 | Website https://metsera.com | ||
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.